The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While https://susanmfbn491305.wikiconversation.com/7790841/glp_3_retatrutide_a_comparative_analysis